Phobic Disorders Clinical Trial
Official title:
In Vivo Versus Augmented Reality Exposure for Small Animal Phobia Treatment: A Randomized Controlled Trial
The aim of this study is to explore the differential efficacy of in vivo exposure versus
augmented reality exposure in the treatment of specific phobia (small animals).
The hypothesis is: There will not be significant statistical differences in the efficacy of
in vivo exposure therapy versus augmented reality exposure in the treatment of specific
phobia (small animals).
Among anxiety disorders, specific phobias are highly prevalent (around 7.2% and 11.3% in the
general population). Cockroach or spider phobia is a type of specific phobia, animal type.
The gold standard for the treatment of specific phobia (included small animal phobia) is in
vivo exposure. Most phobia sufferers (60-80%) never seek treatment. Besides, not all
patients benefit from in vivo exposure, given that an important amount of them do not accept
the intervention or drop out (around 25%) when they are informed about the intervention
procedure.
Information and Communication Technologies (ICT) like Virtual Reality (VR) and Augmented
Reality (AR) are pioneer applications that can improve treatment adherence and acceptance.
There exist some studies offering preliminary evidence of the efficacy of AR for the
treatment of small animal phobia. However, there are not any controlled study exploring the
differential efficacy of ICT-based exposure interventions versus in vivo exposure. In the
present study the differential efficacy of AR exposure versus in vivo exposure for the
treatment of small animal phobia is explored with a between subject randomized controlled
trial. A pre-treatment assessment will be conducted in order to establish the diagnosis and
evaluate the main outcome measures. All participants will receive an intensive exposure
session following Öst guidelines, (in vivo exposure in one experimental condition and AR
exposure in the other experimental condition). After the treatment a post-treatment
assessment will be carried out as well as follow-up assessments at 3- and 12-month after
treatment completion.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01963806 -
ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder
|
N/A | |
Completed |
NCT00121069 -
Study of Escitalopram in the Treatment of Specific Phobia
|
Phase 2/Phase 3 | |
Recruiting |
NCT03653923 -
Neurophysiological Correlates of Exposition Therapy in Spider Phobia
|
N/A | |
Completed |
NCT00184106 -
RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo
|
Phase 4 | |
Completed |
NCT00051220 -
Treatment for Specific Phobias in Children
|
Phase 1/Phase 2 | |
Completed |
NCT02310152 -
Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)
|
N/A | |
Completed |
NCT02387047 -
Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly
|
N/A | |
Completed |
NCT00000370 -
Treatment of Social Phobia
|
N/A | |
Completed |
NCT03012035 -
The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants
|
N/A | |
Completed |
NCT02007694 -
Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03188575 -
Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT
|
N/A | |
Completed |
NCT02432703 -
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
|
Phase 2 | |
Terminated |
NCT01574014 -
Glucocorticoid Treatment for Social Phobia
|
Phase 2 | |
Completed |
NCT00734422 -
Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02336802 -
Threat-Avoidance Learning in Anxiety Patients
|
N/A | |
Completed |
NCT00104195 -
A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions
|
Phase 1 | |
Completed |
NCT00035412 -
St. John's Wort Versus Placebo in Social Phobia
|
Phase 2 | |
Completed |
NCT00128401 -
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
|
Phase 2 | |
Recruiting |
NCT02020824 -
Virtual Reality and Concept of Control in the Treatment of Acrophobia
|
N/A | |
Terminated |
NCT01623583 -
Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias
|
Phase 4 |